• Sitemap
  • Contact us

pISSN 2950-9114 eISSN 2950-9122
Article View

Original Article

Lab Med Qual Assur 2022; 44(4): 216-225

Published online December 31, 2022

https://doi.org/10.15263/jlmqa.2022.44.4.216

Copyright © Korean Association of External Quality Assessment Service.

Performance Evaluation of BRCA1/2 Genetic Test Using Next-Generation Sequencing Based on Target Capture Method

Aram Kim1 , Ji Hyun Kim1,2 , Sung Hyun Seo2 , Seunghoo Lee1 , Woochang Lee1 , and Sail Chun1

1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul; 2Dxome Co. Ltd., Seongnam, Korea

Correspondence to:Woochang Lee
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel +82-2-3010-4506
E-mail wlee1@amc.seoul.kr

Received: April 12, 2022; Revised: August 9, 2022; Accepted: August 9, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: BRCA1 and BRCA2 pathogenic variants are important genetic factors associated with cancers and biomarkers of breast and ovarian cancer. Although Sanger sequencing is regarded as the gold standard for BRCA1/2 testing, this method is time-consuming and labor-intensive. In this study, we performed next-generation sequencing (NGS) using DxSeq BRCA1/2 (Dxome, Korea), a kit in which the target capture method is applied to detect BRCA1/2 variants, and compared the performance of the kit with that of Sanger sequencing and BRCAaccuTest (NGeneBio, Korea), another approved kit based on the amplicon NGS method.
Methods: A total of 114 samples was evaluated using BRCA1/2 testing. All samples were confirmed using Sanger sequencing. We performed NGS analysis with the DxSeq BRCA1/2 and compared the results with those of Sanger sequencing and the BRCAaccuTest.
Results: Comparison of the sequencing results obtained using NGS with DxSeq BRCA1/2 and Sanger sequencing showed that the clinical sensitivity, clinical specificity, positive predictive value, and negative predictive value were 100%. The overall agreement between DxSeq BRCA1/2 and BRCAaccuTest was 89.1%. The BRCAaccuTest did not detect five cases: four insertion-deletion variants and one copy number variation.
Conclusions: DxSeq BRCA1/2, an NGS kit based on the target capture method, showed similar performed as that of Sanger sequencing. In addition, the performance of this kit was superior to that of another NGS kit using the amplicon method. Thus, the DxSeq BRCA1/2 kit can be used to detect genetic causes of breast and ovarian cancer in clinical laboratories.

Keywords: BRCA1 genes, BRCA2 genes, Next-generation sequencing

Supplementary File


Share this article on :

Stats or metrics